Showing results (441-450 of 561) with videos related to
Sort By:
Pageof 57
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.International Journal of Radiation Oncology, Biology, Physics|October 2, 2024
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate CancerAmy J Wisdom, Beow Y Yeap, Jeff M Michalski, et al.International Journal of Radiation Oncology, Biology, Physics|July 25, 2022
A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate CancerLiat Hammer, Ralph Jiang, Jason Hearn, et al.JCO Precision Oncology|June 6, 2025
Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 MenAngela Y Jia, Yilun Sun, Maitry Patel, et al.The Lancet. Oncology|October 17, 2016
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysisShuang G Zhao, S Laura Chang, Daniel E Spratt, et al.International Journal of Radiation Oncology, Biology, Physics|July 25, 2025
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)Daniel A Hamstra, James J Dignam, Deborah W Bruner, et al.JCO Precision Oncology|October 24, 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital HistopathologyJonathan David Tward, Huei-Chung Huang, Andre Esteva, et al.Journal of the National Cancer Institute|October 16, 2018
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic TargetShuang G Zhao, Jonathan Lehrer, S Laura Chang, et al.Cancer|April 15, 2023
A novel prostate cancer subtyping classifier based on luminal and basal phenotypesAdam B Weiner, Yang Liu, Alex Hakansson, et al.Prostate Cancer and Prostatic Diseases|November 14, 2019
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomyJoseph Marascio, Daniel E Spratt, Jingbin Zhang, et al.Pageof 57